OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)

Market Cap	179.29B +59.5%
Revenue (ttm)	87.58B +11.1%
Net Income	11.18B +17.6%
EPS	731.00 +17.4%
Shares Out	17.65M
PE Ratio	13.90
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	273,866
Average Volume	1,094,982
Open	10,850
Previous Close	10,850
Day's Range	10,240 - 11,180
52-Week Range	5,610 - 14,040
Beta	0.66
RSI	54.41
Earnings Date	Jan 23, 2026

About OPTUS Pharmaceutical

OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Cheongju, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2002
• Employees: 159
• Stock Exchange: KOSDAQ
• Ticker Symbol: 131030

Financial Performance

In 2024, OPTUS Pharmaceutical's revenue was 81.90 billion, an increase of 13.09% compared to the previous year's 72.43 billion. Earnings were 10.31 billion, a decrease of -4.20%.